tepotinib Report issue

Small molecule Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now
c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF). These inhibitors may have therapeutic application in the treatment of various types of cancers.   Wikipedia

Chemistry

  • SMILES: CN1CCC(COc2cnc(nc2)c3cccc(CN4N=C(C=CC4=O)c5cccc(c5)C#N)c3)CC1
  • InChIKey: AHYMHWXQRWRBKT-UHFFFAOYSA-N
  • Mol. Mass: 492.58
  • ALogP: 4.01
  • ChEMBL Molecule:
    tepotinib  
More Chemistry

Pharmacology

Alternative names

emd-1214063 | msc-2156119 | msc2156119j | msc-2156119j | tepotinib

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Brain Neoplasms (Phase 1)

Carcinoma, Hepatocellular (Phase 1/Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colorectal Neoplasms (Phase 2)

Healthy Volunteers (Phase 1)

Liver Diseases (Phase 1)

Mutation (Phase 2)

Neoplasms (Phase 2)

Proto-Oncogene Proteins c-met (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 21
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue